Plastic Surgery Instruments Market Size Worth $1.9 Billion By 2026

The global plastic surgery instruments market size is expected to reach USD 1.9 billion by 2026, according to a new report by Grand View Research, Inc, exhibiting a CAGR of 8.8%. Increasing number of surgical procedures coupled with technological advancements is anticipated to drive the market. Moreover, increasing awareness about plastic or reconstructive surgeries and improving affordability of related healthcare services are expected to aid growth over the forecast period.

Several key players are investing on R&D to launch innovative products. Moreover, rise in disposable income, improvement of standard of living, high social media influence, and increase in awareness among people are some of the factors boosting the number of surgical procedures. Plastic and reconstructive surgeries are performed mainly to restore tissue function and improve the body’s appearance caused by trauma, burns, birth disorders, or any other disease.

According to WHO, 10 million people are injured or disabled due to road accidents every year, leading to extensive wound surgeries. This is expected to increase the number of plastic surgeries. The number of breast augmentation procedures has also increased by 4.3%, from 313,735 procedures in 2018 to 300,378 procedures in 2017. In addition, women with implants are also required to undergo additional surgeries due to complications such as leakage, scars, or shift of implants. High cost of implants coupled with rising demand is propelling demand for surgical instruments for breast procedures, thereby driving the overall market. Moreover, with rising healthcare expenditure in emerging economies, the number of plastic and cosmetic surgeries has increased to enhance aesthetic appeal, thus driving growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/plastic-surgery-instruments-market

Further key findings from the study suggest:

North America accounted for largest share owing to favorable reimbursement policies, presence of key local market players, and government initiatives
Asian countries are estimated to show the highest growth rate of over 12%, due to rising technological advancements, increasing investments, improving reimbursement scenario, and growing medical tourism
Handheld surgical instruments dominated the products segment with over 70% share in 2018 driven by easy availability and high use of these instruments in invasive and minimally invasive surgeries
Some of the key companies of plastic surgery instruments market are Sklar Surgical Instruments; Zimmer Biomet holdings, Inc.; B. Braun Melsungen AG; Blink Medical Ltd.; Bolton Surgical Ltd.; Integra Life Sciences; Karlz Storz; and Anthony Product, Inc.

Scooters Market Size Worth $33.58 Billion By 2030

The global scooters market size is expected to reach USD 33.58 billion by 2030, at a CAGR of 0.1% over the forecast period, according to a study conducted by Grand View Research, Inc. Declining raw material prices, the growing adoption of electric scooter sharing service, and rising consumer awareness towards eco-friendly transportation is projected to fuel the market growth. As the automotive industry is evolving, the uncertainties over the adoption of electric scooters related to the lack of charging infrastructure in developing economies are gaining prominence. It is forcing the manufacturers to undertake strategies to make design and specification alterations in line with the consumer’s expectations to comprehend the full potential of the evolving electric two-wheeler industry. Hence, the introduction of home charging solutions, battery swapping stations, and product-related innovations have boosted the revenue growth in the market for electric scooters over the past two years and is projected to continue a proliferated trend over the next eleven years.

The role electric scooters is portrayed in meeting the standards for zero-emissions is contributing significantly to reducing the carbon emission gap by 2025. The consumption of electricity in these vehicles can be managed with proper energy and power infrastructure planning, which is further mitigated by evolving technologies such as solar-powered vehicles and vehicle-to-grid technologies.

In addition, the key players are focusing on innovations to expand their reach. For instance, Gogoro, Inc. is offering its customers battery-swapping network to offset the cost of purchasing an electric scooter by removing the battery, which accounts for around 35% to 50% of the entire vehicle cost. Furthermore, the charging system manufacturers are collaborating with automakers and researchers to develop strategies that can facilitate scooters access to clean energy from renewable sources such as solar power, wind energy, among others, thus influencing the market growth over the forecast period.

Asia Pacific dominated the market in 2019 and is projected to continue its dominance over the forecast period. Most of the players manufacturing scooters belong to China, Japan, South Korea, and India. These players generate revenue by selling their products internationally, either through their distribution channel or through the OEM channel. The role of governments of various economies such as India, China, and Japan, in setting up standards and regulations for vehicle charging infrastructure, is anticipated to have a positive impact on the regional market growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/scooters-market

Further key findings from the report suggest:

The normal scooters segment is expected to dominate the overall market owing the easy availability of petrol, striking mileage, and safe long-distance drive established scooters as an everyday commuter vehicle. The segment is expected to reach USD 31.99 billion by 2030
The conventional electric scooters segment is expected to dominate the segment and the trend is expected to continue over the forecast period. The segment is anticipated to reach USD 1.16 billion by 2030. A lower-priced conventional scooter would incur fewer expenses and lower Total Cost of Ownership (TCO) compared to a normal scooter
Asia Pacific is projected to account for the majority share of the market over the forecast period. Fluctuating fuel price and air pollution caused by gas emissions have encouraged the regional demand for electric scooters, which is projected to drive the regional market

Biopharmaceutical 3PL Market Size Worth $120.64 Billion By 2025

The global biopharmaceutical third party logistics market size is expected to reach USD 120.64 billion by 2025, at a CAGR 4.9% over the forecast period, according to a new report by Grand View Research, Inc. The market for biopharmaceutical third party logistics (3PL) is majorly driven by rising demand for temperature controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales. Rising adoption of automated storage and retrieval systems in the emerging countries is an ongoing trend in the pharmaceutical logistics companies that has gained a significant traction.

Furthermore, the trend of shifting from small molecule drugs to biopharmaceuticals, mainly vaccines and biologics, is projected to drive the market. Since, these small molecule drugs are temperature sensitive products, demand for temperature controlled transportation and storage increases and thus is responsible for the market growth. As of now, the pharmaceutical sales through distributors have grown from USD 304.6 billion in 2013 to USD 440.2 billion in 2016. However, the average number of manufacturers per distributor had declined from 1,474 in 2014 to 1,211 in 2016. This data depicts that there is an increase in quantity of pharmaceutical products being distributed, and thus, is expected to surge the demand for 3PL services.

Additionally, environmental concerns and cost have caused a slight shift in the means of transport used for commercial product, moving from airway to seaway shipping and in roadways from truck to intermodal (both rail and truck). The intermodal transport is majorly used by these pharmaceutical companies to reduce the carbon footprint. The ongoing trend shows that the pharmaceutical manufacturers have shifted towards sea freight to reduce the cost and risk factor. Although for cold chain products, the companies still prefer air freight. However, some of the large pharmaceutical companies are planning to transport 70% of their products via ocean freight including cold chain products.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-third-party-logistics-3pl-market

Further key findings from the report suggest:

In 2018, non-cold chain logistics held the largest market share in terms of revenue owing to the sales of a large number of drugs that do not require any temperature control
Cold chain logistics segment is expected to register the faster CAGR over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits
Warehousing and storage held the largest market share among the types of services in 2018
Asia pacific expected to emerge with the fastest CAGR over the forecast period owing to adoption of medicines from aging population and shift of drug sales from brand manufacturers to generic
Key players operating in the biopharmaceutical third party logistics market include DHL International GmbH., SF Express, United Parcel Service of America, Inc, AmerisourceBergen Corporation, DB Schenker, Kuehne and Nagel, Kerry logistics network limited and Agility

Pharmaceutical Grade Lactose Market Worth $254.8 Million By 2025

The global pharmaceutical grade lactose market size is expected to reach USD 254.8 million by 2025 at a 4.6% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Rising inclination toward preventive healthcare across the globe is estimated to boost product use over the forecast period.

Increasing investments by local and foreign players in the pharmaceutical manufacturing sector, especially in developing economies such as India and Brazil, is expected to have a positive influence on industry growth. Furthermore, increased access to medication through generic drug production and development of innovative treatments for chronic diseases has resulted in the growth of the drug manufacturing industry, thereby propelling product demand.

Raw material prices and operational and transportation costs are key factors that define final product price. Intense competition in the industry is expected to put pressure on prices, resulting in a decline in product price. In addition, higher product prices have lowered buyers’ interest, owing to availability of substitutes, which is also expected to hamper growth.

Stringent government regulations associated with the use of pharmaceutical grade lactose are expected present a barrier to entry of new players in the market. In addition, high initial cost and operation cost associated with production machinery is expected to further discourage new entrants, thereby lowering their threat.

The industry is characterized by presence of major industry players focussing on research and development activities in order to reduce overall manufacturing cost by using innovative techniques. Participants have been adopting competitive strategies such as setting up new manufacturing facilities to magnify their regional presence.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/pharmaceutical-grade-lactose-market

Further key findings from the report suggest:

Europe dominated the industry in 2017 in terms of product consumption and was valued at USD 74.7 million owing to increasing product adoption and well-established pharmaceutical industry
Asia Pacific accounted for 33.4% of the total revenue in 2017, owing to government initiatives to provide affordable prescription drugs and highest number of FDA-approved pharmaceutical lactose products in the region
The industry is characterized by increasing integration across the value chain, with participants looking to expand their footprint and strengthen their position in both manufacturing and distribution

Healthcare Reimbursement Market Size Worth $20.46 Trillion By 2026

The global healthcare reimbursement market size is expected to reach USD 20.45 trillion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 19.0% during the forecast period. Supportive government initiatives along with rising cost of prescription medicines are likely to work in favor of the market.

Hospital, Human Heart, Medical Exam, Pharmacy, Currency

The U.S. Affordable Care Act focuses on controlling and minimizing costs of healthcare. The law supports innovative methods to deliver medical care to reduce healthcare costs and makes affordable health insurance available to more people. Since the Obamacare came into effect in 2014, the number of uninsured children under the age of 18 in the U.S. reduced to 5.0% in 2015 as compared to 9% in 2008.

In addition, the Centre for Medicare & Medicaid Services is working towards delivery of reliable high-quality care, endorsement of efficient results in healthcare system, and making health insurance affordable for millions of Americans who are seeking and getting coverage. The Medicaid spending in the U.S. grew by 3.9% in 2016 or 17.0% of the total National Health Expenditure. And Medicare spending grew by 3.6% in 2016 or 20.0% of the total National Health Expenditure.

The underpaid segment is anticipated to dominate the market through 2026 owing to growing cases of frauds against government healthcare programs and increasing use of healthcare services that are not medically required. There have been several cases where businesses and individuals have defrauded federal and state government healthcare programs by submitting false claims for healthcare services, treatment, pharmaceutical, and medical devices that were never rendered.

Also, the rivalry among healthcare providers and rising pressure from commercial and public payers to reduce costs as well as to improve care are shifting their focus towards value-based care models from volume-based healthcare models.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/healthcare-reimbursement-market

Further Key Findings From the Study Suggest:

Underpaid emerged as the largest segment in 2017 owing to increasing number of insurance plans that do not cover full reimbursement
On the basis of payers, private players accounted for the leading share in the market in 2017 owing to presence of a large number of private players
North America dominated the market in 2017. A raft of insurance players and strong reimbursement framework are facilitating the dominance of the region
The market in Asia Pacific is projected to witness rapid growth during the forecast period owing to rising penetration of insurance services in rural and urban areas
Some of the market players are UnitedHealth Group, Allianz, Aviva, Aetna, Nippon Life Insurance, CVS Health, WellCare Health Plans, BNP Paribas, The Blue Cross Blue Shield Association, and AgileHealthInsurance.

Aortic Aneurysm Market Size Worth $4.71 Billion By 2026

The global aortic aneurysm market size is estimated to reach USD 4.71 billion by 2026 registering a CAGR of 8.6%, according to a new report by Grand View Research, Inc. Growing geriatric population in developed countries and rise in the number of tobacco smokers are expected to be the key factors driving the global market. Technological advancements in endovascular surgical procedures will augment the market growth further.

Cases of Abdominal Aortic Aneurysms (AAAs), especially in men aged 65 years and above, surpassed the number of Thoracic Aortic Aneurysm Repair (TAA) by threefold. This has increased the demand for advanced stent-graft systems for AAA. Due to the lack of multiple treatment options and being a complex procedure, TAA procedures are fewer. This offers a lucrative opportunity to the manufacturers for developing advanced products for Thoracic Endovascular Aneurysm Repair (TEVAR).

Companies in the market focus on M&A activities to gain higher market share. For instance, leading companies, such as Medtronic, Endologix, and Terumo, acquired smaller firms to expand their product portfolios and geographical reach. In addition, recent FDA approvals have aided in overall market growth. For example, in 2016, Cook Medical received commercialization rights for its Zenith product line in the U.S market for TEVAR.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/aortic-aneurysm-market

Further key findings from the study suggest:

In 2018, AAA segment held the largest share of the global aortic aneurysm market on account of high disease incidences
Stent grafts held a major market share, in terms of sales revenue, in 2018, as they have more than 50% share in the overall surgical treatment cost of a patient
Endovascular Aortic Aneurysm Repair (EVAR), which includes minimally invasive surgeries, is expected to be the fastest-growing segment in future as it is more efficient than open aneurysm due to fewer postsurgical adverse effects
North America held the highest revenue share in 2018 followed by Europe on account of well-established healthcare infrastructure, access to advanced screening and diagnostic tools for AAA, and favorable reimbursement scenario in the region
Cook Medical Devices Pvt. Ltd., Medtronic PLC, Lifetech Scientific Corp., and Gore Medical are some of the key companies in the global market

Artificial Intelligence In Healthcare Market Worth $31.3 Billion By 2025

The global artificial intelligence in healthcare market size is expected to reach USD 31.3 billion by 2025, growing at a CAGR 41.5% over a forecast period, according to a new report by Grand View Research, Inc. The rising demand to reduce healthcare costs, increasing adoption of precision medicine, growing importance of big data in healthcare, and declining hardware costs are some factors propelling adoption of AI technology in healthcare industry. Moreover, rise in potential applications of AI-based tools in medical care and growth in venture capital investments are anticipated to aid growth over the forecast period.

Rise in the number of cross-industry collaborations is anticipated to fuel growth. For instance, in March 2018,Microsoft announced partnership with Apollo Hospitals, one of the prominent healthcare systems in India. The partnership was focused on developing and deploying new machine learning models for predicting the risk of developing cardiac diseases and aid doctors in treatment planning. Increase in venture capital funding is a key factor propelling growth of AI start-ups, which is further contributing to market growth.

The adoption of AI in healthcare is increasing, as healthcare providers are focused on enhancing patient care further. The adoption of this technology in healthcare has various benefits, both patients and healthcare providers. AI enables personalized care, based on body constitution and past medical history. Moreover, the shortage of physicians in some countries is anticipated to increase demand for AI in healthcare.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-healthcare-market

Further key findings from the study suggest:

In 2018, software solutions held the largest revenue share owing to the development of AI-based software solutions for the healthcare sector
Clinical trials held the largest revenue share in 2018, and this can be attributed to the growing focus of pharmaceutical companies on incorporating AI in automation of clinical trial processes.
North America held the largest revenue share, owing to high adoption of healthcare IT solutions in the region and availability of well-established healthcare infrastructure
Asia Pacific is expected to exhibit the fastest CAGR over the forecast period, owing to growing AI-based start-ups, improving healthcare IT infrastructure, and increasing adoption of advanced technologies.
Some key players are IBM Corporation; NVIDIA Corporation, Nuance Communications, Inc.; Microsoft; Intel Corporation; and DeepMind Technologies Limited

Myasthenia Gravis Treatment Market Size Worth $2.06 Billion By 2026

The global myasthenia gravis treatment market size is expected to reach USD 2.06 billion by 2026 at a CAGR of 7.5% through the forecast period, according to a new report by Grand View Research. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/myasthenia-gravis-mg-treatment-market

Further Key Findings From the Study Suggest:

Medications are expected to obtain the largest market share in the treatment segment. This can be attributed to the high adoption of immunotherapies and the recent approval of promising drugs.
Currently, no cure is available for myasthenia gravis, however patients can be treated with medications and surgery for the management of the symptoms.
North America is likely to dominate the MG treatment market due high healthcare expenditure and favorable reimbursement scenario
The Asia Pacific region is expected to grow at the highest CAGR over the forecast period due to improving healthcare infrastructure and increasing disposable income in the region.
Some of the major companies operating in the market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc.

Hybrid Imaging Market Size Worth $9.8 Billion By 2026

The global hybrid imaging market size is expected to reach USD 9.8 billion by 2026, according to a new report by Grand View Research, Inc., registering a 4.5% CAGR over the forecast period. Increasing demand for accurate diagnostic techniques for cancer and cardiac disorders is expected to drive the market. Rising government initiatives for creating awareness regarding multimodal imaging devices are also expected to contribute toward market growth.

Increasing installation of such devices in research centers and institutions to enhance diagnostics in the field of oncology, cardiology, neurology, and others is expected to boost market growth. Leading players in the market are showcasing various multimodal imaging devices at medical conferences to increase their product reach. However, high cost and complications associated with these devices is expected to impede market growth during the forecast period.

Hybrid imaging devices require skilled professionals to understand the data collected by these combined devices. Therefore, various training programmes are conducted by several non-profit and government funded organizations to increase the adoption of hybrid imaging devices for the diagnosis of a disease.

North America dominated the hybrid/multimodal imaging market in 2018 and is expected to grow at a significant rate during the forecast period. The growth observed in this region is largely due to presence of global players and increasing adoption of advanced equipment such as hybrid imaging devices. Moreover, increasing awareness regarding nuclear medicine and molecular diagnostics in the region is expected to contribute toward the growth in this region.

Asia Pacific is expected register the strongest growth over the forecast period. This can be primarily attributed to growing usage of advanced devices such as PET/CT systems in radiology departments across emerging economies. Thriving medical tourism in numerous countries has piqued the interest of global market players, who are looking to invest in the development and launch of advanced software in the region. The Europe market is fueled by ongoing efforts by various non-profit organizations in conducting educational and training programs for scientists, physicians, technologists, physicists, radiographers, and others in the field.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/hybrid-imaging-market

Further key findings from the report suggest:

PET/CT systems held the largest share in 2018 based on type, and the segment is expected to grow at a significant pace due to increasing development and installation of these devices in various end users such as hospitals and diagnostic centers
SPET/CT systems segment in hybrid imaging market will exhibit the fastest growth rate during the forecast period. Data captured by SPET/CT helps in understanding the detailed morphology and pathogenesis of a disease, thereby enhancing the quality of diagnostic output
In 2018, the oncology segment held the dominant share of hybrid imaging systems market by application, largely due to increasing number of cancer cases and growing awareness for cancer diagnosis
The cardiology segment is expected to grow at the fastest pace during the forecast period. Cardiac hybrid imaging helps in accurately capturing morphological and functional information in a single setting, thereby easing the diagnosis of cardiac disorders
Hospitals held the largest market share in 2018 on the basis of end use, mainly due to higher installation of technologically advanced devices for early diagnosis and treatment of a disease
Geographically, Asia Pacific is expected to register the fastest growth rate during the forecast period due to increasing number of radiology departments in the region and launch of advanced software by leading players.

Tenant Billing Software Market Size Worth $544.21 Million By 2027

The global tenant billing software market size is expected to reach USD 544.21 million by 2027, registering a CAGR of 8.4% over the forecast period, according to a new report by Grand View Research, Inc. Rapidly growing adoption of automatic tenant metering and smart grid technology is a primary factor propelling the growth of the market. The market growth can be ascribed to growing demand for real-time tenant utility consumption.

Several commercial properties still use manual tenant metering and bill generation as part of their tenant sub metering workflow. However, the manual metering not only makes the process slow but often builds several errors and inconsistencies for owners and occupants. Whereas, automated metering tracks revenue recovery in real-time and drills down to individual occupants. Moreover, it offers improved experience by showing occupant’s real-time transparency into their utility costs.

Rapidly increasing number of retail stores, hotels, business buildings, airports, and industrial sites is also offering promising growth prospects for the market. North America accounted for the largest market share in 2019 on account of rising demand for advanced tenant billing software in the region. Furthermore, enterprises of all sizes are creating a huge demand for cloud-based billing software in North America, thus boosting the market growth in this region.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/tenant-billing-software-market

Further key findings from the study suggest:

The tenant billing software market is anticipated to witness substantial growth during the forecast period owing to rising adoption of machine learning and IoT in various residential and commercial areas
The cloud deployment segment accounted for the largest market share in 2019 owing to increasing adoption among small, medium, and large enterprises and benefits offered in terms of decreasing disputes with occupants
The on-premise deployment segment is expected to witness significant growth over the forecast period owing to the benefits offered including easy integration with the enterprise’s existing IT infrastructure and high level of data security
Based on application, the commercial segment is expected to witness the fastest growth over the forecast period owing to increasing number of shopping stores, hotels, and business buildings
North America dominated the market in 2019 owing to the extensive adoption of cloud-based tenant billing software by enterprises of all sizes, coupled with growing real estate industry in the region
Key players in the market include Delmon Solution; Commercial Water & Energy Co.; Honeywell International Inc.; Entronix Energy Management, Inc.; Enertiv; TEAM (Energy Auditing Agency Ltd.); Accuenergy Ltd; MACH Energy; SystemsLink 2000 Ltd; Semsys; and IOTomation Ecotech Pvt. Ltd. New product or software development remains a key strategy among the leading players in the market